Toronto Dominion Bank Argenx Se Transaction History

Toronto Dominion Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$356.95 - $413.29 $15,348 - $17,771	43 Added 16.54%	303 $119,000
Q4 2023 Feb 13, 2024	SELL	$338.91 - $506.01 $2,033 - $3,036	-6 Reduced 2.26%	260 $98,000
Q3 2023 Feb 14, 2024	BUY	$369.35 - $548.43 $62,420 - $92,684	169 Added 174.23%	266 $130,000
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $62,420 - $92,684	169 Added 174.23%	266 $130,000
Q2 2023 Feb 14, 2024	SELL	$360.14 - $422.58 $58,702 - $68,880	-163 Reduced 62.69%	97 $38,000
Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $32,420 - $39,154	97 New	97 $36,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

Stay updated on Toronto Dominion Bank with notifications on news.